Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma

Journal of Clinical Oncology

Volumn 24, Issue 7, 2006, Pages 1169-1177

  Cesana, Giovanni C ^a   DeRaffele, Gail ^a   Cohen, Seth ^a   Moroziewicz, Dorota ^a   Mitcham, Josephine ^a   Stoutenburg, John ^a   Cheung, Ken ^a   Hesdorffer, Charles ^a   Kim Schulze, Seunghee ^a   Kaufman, Howard L ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; ANTINEOPLASTIC AGENT; INTERLEUKIN 2 RECEPTOR;

ARTICLE; BLOOD SAMPLING; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; DEMOGRAPHY; DENSITY GRADIENT CENTRIFUGATION; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; ADULT; CD4 LYMPHOCYTE COUNT; CELL SEPARATION; IMMUNOLOGY; KIDNEY TUMOR; LYMPHOCYTE COUNT; MIDDLE AGED; PATHOLOGY; SKIN TUMOR; T LYMPHOCYTE;

ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; LYMPHOCYTE COUNT; MALE; MELANOMA; MIDDLE AGED; PHENOTYPE; RECEPTORS, INTERLEUKIN-2; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 33644988431     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.6830     Document Type: Article

References (46)

1. Nelson BH, Willerford DM: Biology of the interleukin-2 receptor. Adv Immunol 70:1-81, 1998
2. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116, 1999
3. Fyfe G, Fisher RI, Rosenberg SA, et al: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688-696, 1995
4. Fisher RI, Coltman CA Jr, Doroshow JH, et al: Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells: A phase II clinical trial. Ann Intern Med 108:518-523, 1988
5. Sadlack B, Merz H, Schorle H, et al: Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75:253-261, 1993
6. Sadlack B, Kuhn R, Schorle H, et al: Development and proliferation of lymphocytes in mice deficient for both interleukins-2 and -4. Eur J Immunol 24:281-284, 1994
7. Sadlack B, Lohler J, Schorle H, et al: Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol 25:3053-3059, 1995
8. Shevach EM: CD4+ CD25+ suppressor T cells: More questions than answers. Nat Rev Immunol 2:389-400, 2002
9. Wolf AM, Wolf D, Steurer M, et al: Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606-612, 2003
10. Liyanage UK, Moore TT, Joo HG, et al: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756-2761, 2002
11. Woo EY, Yeh H, Chu CS, et al: Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168:4272-4276, 2002
12. Ichihara F, Kono K, Takahashi A, et al: Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9:4404-4408, 2003
13. Ormandy LA, Hillemann T, Wedemeyer H, et al: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65:2457-2464, 2005
14. Sasada T, Kimura M, Yoshida Y, et al: CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: Possible involvement of regulatory T cells in disease progression. Cancer 98:1089-1099, 2003
15. Curiel TJ, Coukos G, Zou L, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949, 2004
16. Cohen S, Kaufman H: The current status of high dose Interleukin-2 (IL-2) for the treatment of metastatic melanoma. Biol Ther Cancer 3:3-11, 2005
17. Hoffmann P, Eder R, Kunz-Schughart LA, et al: Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood 104:895-903, 2004
18. Dieckmann D, Plottner H, Berchtold S, et al: Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 193:1303-1310, 2001
19. Lanzavecchia A, Sallusto F: Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 17:326-332, 2005
20. Gottlieb DJ, Prentice HG, Heslop HE, et al: Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemoradiotherapy for hematological malignancy. Blood 74:2335-2342, 1989
21. Rosenberg SA, Yang JC, White DE, et al: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response. Ann Surg 228:307-319, 1998
22. Scheffold A, Huhn J, Hofer T: Regulation of CD4+CD25+ regulatory T cell activity: It takes (IL-) two to tango. Eur J Immunol 35:1336-1341, 2005
23. Marincola FM, Venzon D, White D, et al: HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy. Cancer Res 52:6561-6566, 1992
24. Rubin JT, Elwood LJ, Rosenberg SA, et al: Immunohistochernical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res 49:7086-7092, 1989
25. Horikoshi T, Ito S, Wakamatsu K, et al: Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 73:629-636, 1994
26. Bosserhoff AK, Kaufmann M, Kaluza B, et al: Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57:3149-3153, 1997
27. Sirott MN, Bajorin DF, Wong GY, et al: Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysis. Cancer 72:3091-3098, 1993
28. Wang E, Miller LD, Ohnmacht GA, et al: Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 62:3581-3586, 2002
29. Janik JE, Sznol M, Urba WJ, et al: Erythropoietin production: A potential marker for interleukin-2/interferon-responsive tumors. Cancer 72:2656-2659, 1993
30. Atkins M, Regan M, McDermott D, et al: Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11:3714-3721, 2005
31. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057-1061, 2003
32. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat Immunol 4:330-336, 2003
33. Khattri R, Cox T, Yasayko SA, et al: An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 4:337-342, 2003
34. Lundqvist A, Palmborg A, Pavlenko M, et al: Mature dendritic cells induce tumor-specific type 1 regulatory T cells. J Immunother 28:229-235, 2005
35. Battaglia M, Gianfrani C, Gregori S, et al: IL-10-producing T regulatory type 1 cells and oral tolerance. Ann N Y Acad Sci 1029:142-153, 2004
36. Kwon B, Yu KY, Ni J, et al: Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand. J Biol Chem 274:6056-6061, 1999
37. Gurney AL, Marsters SA, Huang RM, et al: Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol 9:215-218, 1999
38. Shimizu J, Yamazaki S, Takahashi T, et al: Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3:135-142, 2002
39. Hugh RS, Whitters MJ, Piccirillo CA, et al: CD4(+)CD25(+) immunoregulatory T cells: Gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16:311-323, 2002
40. Malek TR: The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol 74:961-965, 2003
41. Graca L, Le Moine A, Lin CY, et al: Donor-specific transplantation tolerance: The paradoxical behavior of CD4+CD25+ T cells. Proc Natl Acad Sci USA 101:10122-10126, 2004
42. Jin P, Panelli MC, Marincola FM, et al: Cytokine polymorphism and its possible impact on cancer. Immunol Res 30:181-190, 2004
43. Atkins MB: Interleukin-2: Clinical applications. Semin Oncol 29:12-17, 2002
44. Yang JC, Sherry RM, Steinberg SM, et al: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21:3127-3132, 2003
45. McDermott DF, Regan MM, Clark JI, et al: Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23:133-141, 2005
46. Rabkin CS, Yang Q, Goedert JJ, et al: Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus-1-infected individuals. Blood 93:1838-1842, 1999